These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6579706)

  • 1. The relationship between dose, pharmacokinetics, plasma-concentrations and antithrombotic effects of nafazatrom.
    Philipp E; Ritter W; Patzschke K
    Thromb Res Suppl; 1983; 4():129-33. PubMed ID: 6579706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral nafazatrom in man: effect on inhaled antigen challenge.
    Fuller RW; Maltby N; Richmond R; Dollery CT; Taylor GW; Ritter W; Philipp E
    Br J Clin Pharmacol; 1987 Jun; 23(6):677-81. PubMed ID: 3038156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
    Klitzke AK
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575).
    Strasser T; Fischer S; Weber PC
    Biochem Pharmacol; 1985 Jun; 34(11):1891-4. PubMed ID: 2988560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
    Massad L; Plotkine M; Boulu RG
    Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals.
    Sevilla MD; Neta P; Marnett LJ
    Biochem Biophys Res Commun; 1983 Sep; 115(3):800-6. PubMed ID: 6312995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro effects of nafazatrom (Bay g 6575), an antithrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue.
    Fischer S; Struppler M; Weber PC
    Biochem Pharmacol; 1983 Jul; 32(14):2231-6. PubMed ID: 6688182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ; Parratt JR
    J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of nafazatrom-induced inhibition of rat uterus contractions in vitro.
    Cantabrana B; Velasco G; Andrès-Trelles F; Hidalgo A
    Arch Int Pharmacodyn Ther; 1989; 301():285-98. PubMed ID: 2560365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of nafazatrom in body fluids by high-performance thin-layer chromatography with post-chromatographic derivatization.
    Ritter W
    J Chromatogr; 1984 May; 290():97-105. PubMed ID: 6736168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G; Bayorh MA; Stull R; Goldstein DS; Zerbe RL; Ramwell PW; Faden AI
    Circ Shock; 1985; 17(3):223-32. PubMed ID: 3841032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L; Mehta J; Mehta P
    Am Heart J; 1985 May; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafazatrom, an arachidonate metabolism inhibitor, decreases prolactin and GH release.
    Judd AM; Login IS; Ehreth JT; MacLeod RM
    Eur J Pharmacol; 1986 Sep; 128(3):151-6. PubMed ID: 3792440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog.
    Fiedler VB; Mardin M
    J Cardiovasc Pharmacol; 1985; 7(5):983-9. PubMed ID: 2413312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom.
    Fiedler VB
    J Cardiovasc Pharmacol; 1984; 6(2):318-24. PubMed ID: 6200722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiaggregatory efficacy and its time-course after application of acetylsalicylic acid, prostacyclin and nafazatrom in vivo.
    Herrmann KS
    Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):150-8. PubMed ID: 6393886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.